Karuna Therapeutics is a clinical-stage biopharmaceutical company that focuses on transformative medicines for people living with psychiatric and neurological conditions. Co.'s proprietary product candidate, KarXT (xanomeline-trospium), an oral modulator of muscarinic receptors that are located both in the central nervous system (CNS) and various peripheral tissues. KarXT combines xanomeline, a muscarinic agonist, with trospium, an approved muscarinic antagonist, to preferentially stimulate muscarinic receptors in the CNS. Co. is developing KarXT for the treatment of psychosis in adults with schizophrenia as well as for the treatment of psychosis in Alzheimer's disease. We show 20 historical shares outstanding datapoints in our KRTX shares outstanding history coverage, used to compute KRTX market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing KRTX market cap history over the course of time is important for investors
interested in comparing KRTX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of KRTX versus a peer is one thing; comparing
KRTX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like KRTX can fluctuate over the course of history.
With this page we aim to empower investors researching KRTX by allowing them to research the KRTX market cap history. |
Free KRTX Email Alerts:
Video: The Importance of Market Cap
